Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region

PLoS One. 2022 Sep 9;17(9):e0273694. doi: 10.1371/journal.pone.0273694. eCollection 2022.

Abstract

Accurate estimates of natural and/or vaccine-induced antibodies to SARS-CoV-2 are difficult to obtain. Although model-based estimates of seroprevalence have been proposed, they require inputting unknown parameters including viral reproduction number, longevity of immune response, and other dynamic factors. In contrast to a model-based approach, the current study presents a data-driven detailed statistical procedure for estimating total seroprevalence (defined as antibodies from natural infection or from full vaccination) in a region using prospectively collected serological data and state-level vaccination data. Specifically, we conducted a longitudinal statewide serological survey with 88,605 participants 5 years or older with 3 prospective blood draws beginning September 30, 2020. Along with state vaccination data, as of October 31, 2021, the estimated percentage of those 5 years or older with naturally occurring antibodies to SARS-CoV-2 in Texas is 35.0% (95% CI = (33.1%, 36.9%)). This is 3× higher than, state-confirmed COVID-19 cases (11.83%) for all ages. The percentage with naturally occurring or vaccine-induced antibodies (total seroprevalence) is 77.42%. This methodology is integral to pandemic preparedness as accurate estimates of seroprevalence can inform policy-making decisions relevant to SARS-CoV-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Humans
  • Prospective Studies
  • SARS-CoV-2
  • Seroepidemiologic Studies
  • Vaccines*

Substances

  • Antibodies, Viral
  • Vaccines

Grants and funding

Project funded by Texas Department of State Health Services (Grant #HHS000866600001). Funding partners met/meet weekly with the state funding team to review survey findings and two representatives of the funding team are also co-authors on this manuscript.